<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04291768</url>
  </required_header>
  <id_info>
    <org_study_id>190801</org_study_id>
    <secondary_id>2019-003282-17</secondary_id>
    <secondary_id>H-19085920</secondary_id>
    <nct_id>NCT04291768</nct_id>
  </id_info>
  <brief_title>Shortened Antibiotic Treatment of 5 Days in Gram-negative Bacteremia</brief_title>
  <acronym>GNB5</acronym>
  <official_title>Short Course Antibiotic Treatment of Gram-negative Bacteremia: A Multicenter, Randomized, Non-blinded, Non-inferiority Interventional Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Benfield</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hvidovre University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      GNB5 is an investigator-initiated multicentre non-inferiority randomized controlled trial
      which aims to assess the efficacy and safety of shortened antibiotic for patients
      hospitalized with a Gram negative bacteremia with a urinary tract source of infection (GNB).

      Five days after initiation of antimicrobial therapy for GNB, participants are randomized 1:1
      to parallel treatment arms: 5 days (intervention) or minimum 7 days (control) of antibiotic
      treatment. The intervention group discontinues antibiotics at day 5 if clinically stable and
      afebrile. The control group receives antibiotics for a duration of 7 days or longer at the
      discretion of the treating physician.

      The primary outcome is 90-day survival without clinical or microbiological failure to
      treatment, which will be tested with a non inferiority margin of 10%.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Introduction: Prolonged use of antibiotics is closely related to antibiotic-associated
      infections, anti-microbial resistance and adverse drug events. The optimal duration of
      antibiotic treatment for Gram-negative bacteremia (GNB) with a urinary tract source of
      infection is poorly defined.

      Methods and analysis: Investigator initiated multicenter, non-blinded, non-inferiority
      randomized controlled trial with two parallel treatment arms. One arm will receive shortened
      antibiotic treatment of 5 days and the other arm will receive standard antibiotic treatment
      of 7 days or longer. Randomization will occur in equal proportion (1:1) no later than day 5
      of efficacious antibiotic treatment as determined by antibiogram. Immunosuppressed patients
      and those with GNB due to non-fermenting bacilli (Acinetobacter spp, Pseudomonas spp),
      Brucella spp, Fusobacterium spp or polymicrobial growth are ineligible.

      Primary endpoint is 90-day survival without clinical or microbiological failure to treatment.
      Secondary endpoints include all-cause mortality, total duration of antibiotic treatment,
      hospital re-admission and Clostridioides difficile infection. Interim safety analysis will be
      performed after the recruitment of every 100 patients. Given an event rate of 12%, a margin
      of 10% and 90% power, the required sample size to determine non-inferiority is 380 patients.
      Analyses will be performed on both intention-to-treat and per-protocol populations.

      Ethics and dissemination: Approval by Ethics Committee and National Competent Authorities
      will be obtained before initiation of the trial. Results of the main trial and each of the
      secondary endpoints will be submitted for publication in a peer-reviewed journal.

      Impact: Demonstration of non-inferiority will provide needed evidence to safely shorten
      antibiotic treatment duration in GNB with a urinary tract source of infection and thereby
      reduce the risk of adverse events and development of resistance associated with use of
      antibiotics
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 11, 2020</start_date>
  <completion_date type="Anticipated">October 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>90-day survival without clinical or microbiological failure to treatment</measure>
    <time_frame>90 days</time_frame>
    <description>90-day survival without clinical or microbiological failure to treatment as defined:
All-cause mortality from day of randomization and until day 90
Microbiological failure: Recurrent bacteremia due to the same microorganism as verified by sequence analysis occurring from day of randomization and until day 90
Clinical failure: Re-initiation of therapy against Gram-negative bacteremia for more than 48 hours due to clinical worsening suspected to be due to the initial infecting organism and for which there is no alternate diagnosis/pathogen suspected from the day of randomization and until day 90
Distant complications of initial infection, defined by growth of the same bacteria as in the initial bacteremia (e.g. endocarditis, meningitis)
Local suppurative complication that was not present at infection onset (e.g. renal abscess in pyelonephritis)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>14, 30 and 90 days</time_frame>
    <description>Number of deaths by any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total duration of antibiotic treatment</measure>
    <time_frame>90 days</time_frame>
    <description>Days that the participant receives antibiotic treatment for Gram-negative bacteremia, adding intravenous and oral therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type of antibiotic treatment</measure>
    <time_frame>90 days</time_frame>
    <description>Antibiotic treatment for Gram-negative bacteremia given by antibiogram</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of antibiotic treatment</measure>
    <time_frame>90 days</time_frame>
    <description>Duration of antibiotic treatment for Gram-negative bacteremia given by antibiogram</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total length of hospital stay</measure>
    <time_frame>90 days</time_frame>
    <description>Days from the date of hospital admission for Gram-negative bacteremia to the date of discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital re-admission</measure>
    <time_frame>30 and 90 days</time_frame>
    <description>Number of participants with readmissions for reasons related to or unrelated to Gram-negative bacteremia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibiotic adverse events</measure>
    <time_frame>90 days</time_frame>
    <description>Number of participants with adverse events with possible relation to the antibiotic treatment of Gram-negative bacteremia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of antimicrobials after discharge</measure>
    <time_frame>90 days</time_frame>
    <description>Days of antibiotic treatment for any reason after hospital discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe adverse events</measure>
    <time_frame>90 days</time_frame>
    <description>Number of participants with serious adverse events according to International Council of Harmonisation-Good Clinical Practice (ICH-GCP) guidelines</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute kidney injury</measure>
    <time_frame>90 days</time_frame>
    <description>Number of participants with acute kidney injury is defined according to RIFLE criteria as increased creatinine level x 1.5 from baseline or estimated glomerular filtration rate (eGFR) decrease &gt;25% or urine output of &lt;0.5 ml/kg/h for 6 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clostridioides difficile infection</measure>
    <time_frame>90 days</time_frame>
    <description>Number of participants with Clostridioides difficile infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multidrug-resistance organism</measure>
    <time_frame>90 days</time_frame>
    <description>Multidrug-resistance organism defined as identification of resistant bacteria in a clinical specimen obtained only from a clinical infection.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">380</enrollment>
  <condition>Gram-negative Bacteremia</condition>
  <condition>Urinary Tract Infection Bacterial</condition>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Shortened antibiotic treatment of 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard antibiotic treatment of minimum 7 days at the discretion of treating physician</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Shortened antibiotic treatment</intervention_name>
    <description>Shortened antibiotic treatment of 5 days. Participation in the study will only affect treatment duration and will have no influence on the choice of treatment in respect to type and dose of antibiotic treatment.</description>
    <arm_group_label>Intervention group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard antibiotic treatment</intervention_name>
    <description>Standard antibiotic treatment of minimum 7 days at the discretion of treating physician. Participation in the study will only affect treatment duration and will have no influence on the choice of treatment in respect to type and dose of antibiotic treatment.</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;18 years

          -  Blood culture positive for Gram-negative bacteria

          -  Evidence of urinary tract source of infection (positive urine culture or at least one
             clinical symptom compatible with urinary tract infection)

          -  Antibiotic treatment with antimicrobial activity to Gram-negative bacteria
             administrated within 12 hours of first blood culture

          -  Temperature &lt;38°C at randomization

          -  Clinically stabile at randomization (systolic blood pressure &gt; 90 mm Hg, heart rate
             &lt;100 beats/min., respiratory rate &lt;24/minute, peripheral oxygen saturation &gt; 90 %)

          -  Oral and written informed consent

        Exclusion Criteria:

          -  Immunosuppression (Untreated HIV-infection, Neutropenia (absolute neutrophil count &lt;
             1.0 x 109/l, Corticosteroid treatment (10 mg/day prednisone or the equivalent for &gt;30
             days), Chemotherapy, Immunosuppressive agents, Immunosuppressed after solid organ
             transplantation, Asplenia)

          -  Polymicrobial growth in blood culture

          -  Bacteremia with non-fermenting Gram-negative bacteria (Acinetobacter spp, Burkholderia
             spp, Pseudomonas spp), Brucella spp, or Fusobacterium spp

          -  Failure to remove source of infection within 72 hours of first blood culture (e.g.
             change of catheter á demeure)

          -  Pregnancy or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandra Hansen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hvidovre University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sandra Hansen, MD</last_name>
    <phone>+4520544094</phone>
    <email>sandra.skrumsager.hansen@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Thomas Benfield, MD DMSc</last_name>
    <email>thomas.lars.benfield@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital of Aalborg</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Henrik Nielsen, MD DMSc</last_name>
      <email>henrik.nielsen@rn.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jan Gertoft, MD DMSc</last_name>
      <email>jan.gerstoft@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gentofte Hospital</name>
      <address>
        <city>Hellerup</city>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mette Vang Larsen, MD PhD</last_name>
      <email>mette.vang.larsen@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Suzanne Lunding, MD PhD</last_name>
      <email>suzanne.lunding.01@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Herning Hospital</name>
      <address>
        <city>Herning</city>
        <zip>7400</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rajesh Mohey, MD PhD</last_name>
    </contact>
    <contact_backup>
      <email>rajemohe@rm.dk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Nordsjaellands Hospital</name>
      <address>
        <city>Hillerød</city>
        <zip>3400</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Birgitte Lindegaard Madsen, MD PhD</last_name>
      <email>birgitte.lindegaard.madsen@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hvidovre Hospital</name>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra Hansen, MD</last_name>
      <phone>+4520544094</phone>
      <email>sandra.skrumsager.hansen@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kolding Hospital</name>
      <address>
        <city>Kolding</city>
        <zip>6000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Janne Jensen, MD</last_name>
      <email>janne.jensen@rsyd.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Isik Johansen, MD DMSc</last_name>
      <email>isik.somuncu.johansen@rsyd.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Roskilde Hospital</name>
      <address>
        <city>Roskilde</city>
        <zip>4000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lothar Wiese, MD PhD</last_name>
      <email>low@regionsjaelland.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Regionshospitalet Silkeborg</name>
      <address>
        <city>Silkeborg</city>
        <zip>8600</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Britta Tarp, MD PhD</last_name>
      <email>brittarp@rm.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Aarhus</name>
      <address>
        <city>Århus</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lars Østergaard, MD DMSc</last_name>
      <email>larsoest@rm.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <reference>
    <citation>Kang CI, Kim SH, Park WB, Lee KD, Kim HB, Kim EC, Oh MD, Choe KW. Bloodstream infections caused by antibiotic-resistant gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome. Antimicrob Agents Chemother. 2005 Feb;49(2):760-6.</citation>
    <PMID>15673761</PMID>
  </reference>
  <reference>
    <citation>Biedenbach DJ, Moet GJ, Jones RN. Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002). Diagn Microbiol Infect Dis. 2004 Sep;50(1):59-69.</citation>
    <PMID>15380279</PMID>
  </reference>
  <reference>
    <citation>de Kraker ME, Jarlier V, Monen JC, Heuer OE, van de Sande N, Grundmann H. The changing epidemiology of bacteraemias in Europe: trends from the European Antimicrobial Resistance Surveillance System. Clin Microbiol Infect. 2013 Sep;19(9):860-8. doi: 10.1111/1469-0691.12028. Epub 2012 Oct 8.</citation>
    <PMID>23039210</PMID>
  </reference>
  <reference>
    <citation>Søgaard M, Nørgaard M, Dethlefsen C, Schønheyder HC. Temporal changes in the incidence and 30-day mortality associated with bacteremia in hospitalized patients from 1992 through 2006: a population-based cohort study. Clin Infect Dis. 2011 Jan 1;52(1):61-9. doi: 10.1093/cid/ciq069.</citation>
    <PMID>21148521</PMID>
  </reference>
  <reference>
    <citation>European Centre for Disease Prevention and Control (ECDC); European Food Safety Authority (EFSA); European Medicines Agency (EMA). ECDC/EFSA/EMA second joint report on the integrated analysis of the consumption of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from humans and food-producing animals: Joint Interagency Antimicrobial Consumption and Resistance Analysis (JIACRA) Report. EFSA J. 2017 Jul 27;15(7):e04872. doi: 10.2903/j.efsa.2017.4872. eCollection 2017 Jul.</citation>
    <PMID>32625542</PMID>
  </reference>
  <reference>
    <citation>Goossens H, Ferech M, Vander Stichele R, Elseviers M; ESAC Project Group. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet. 2005 Feb 12-18;365(9459):579-87.</citation>
    <PMID>15708101</PMID>
  </reference>
  <reference>
    <citation>Lessa FC, Mu Y, Bamberg WM, Beldavs ZG, Dumyati GK, Dunn JR, Farley MM, Holzbauer SM, Meek JI, Phipps EC, Wilson LE, Winston LG, Cohen JA, Limbago BM, Fridkin SK, Gerding DN, McDonald LC. Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015 Feb 26;372(9):825-34. doi: 10.1056/NEJMoa1408913.</citation>
    <PMID>25714160</PMID>
  </reference>
  <reference>
    <citation>Cunha BA. Antibiotic side effects. Med Clin North Am. 2001 Jan;85(1):149-85. Review.</citation>
    <PMID>11190350</PMID>
  </reference>
  <reference>
    <citation>Tamma PD, Avdic E, Li DX, Dzintars K, Cosgrove SE. Association of Adverse Events With Antibiotic Use in Hospitalized Patients. JAMA Intern Med. 2017 Sep 1;177(9):1308-1315. doi: 10.1001/jamainternmed.2017.1938.</citation>
    <PMID>28604925</PMID>
  </reference>
  <reference>
    <citation>Branch-Elliman W, O'Brien W, Strymish J, Itani K, Wyatt C, Gupta K. Association of Duration and Type of Surgical Prophylaxis With Antimicrobial-Associated Adverse Events. JAMA Surg. 2019 Jul 1;154(7):590-598. doi: 10.1001/jamasurg.2019.0569.</citation>
    <PMID>31017647</PMID>
  </reference>
  <reference>
    <citation>Pollack LA, Srinivasan A. Core elements of hospital antibiotic stewardship programs from the Centers for Disease Control and Prevention. Clin Infect Dis. 2014 Oct 15;59 Suppl 3:S97-100. doi: 10.1093/cid/ciu542.</citation>
    <PMID>25261548</PMID>
  </reference>
  <reference>
    <citation>Rice LB. The Maxwell Finland Lecture: for the duration-rational antibiotic administration in an era of antimicrobial resistance and clostridium difficile. Clin Infect Dis. 2008 Feb 15;46(4):491-6. doi: 10.1086/526535. Review.</citation>
    <PMID>18194098</PMID>
  </reference>
  <reference>
    <citation>Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, Moran GJ, Nicolle LE, Raz R, Schaeffer AJ, Soper DE; Infectious Diseases Society of America; European Society for Microbiology and Infectious Diseases. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011 Mar 1;52(5):e103-20. doi: 10.1093/cid/ciq257. Review.</citation>
    <PMID>21292654</PMID>
  </reference>
  <reference>
    <citation>Corona A, Bertolini G, Ricotta AM, Wilson A, Singer M. Variability of treatment duration for bacteraemia in the critically ill: a multinational survey. J Antimicrob Chemother. 2003 Nov;52(5):849-52. Epub 2003 Sep 30. Erratum in: J Antimicrob Chemother. 2004 Jan;53(1):121. Wilson, A J Peter [corrected to Wilson, A Peter R].</citation>
    <PMID>14519681</PMID>
  </reference>
  <reference>
    <citation>Chotiprasitsakul D, Han JH, Cosgrove SE, Harris AD, Lautenbach E, Conley AT, Tolomeo P, Wise J, Tamma PD; Antibacterial Resistance Leadership Group. Comparing the Outcomes of Adults With Enterobacteriaceae Bacteremia Receiving Short-Course Versus Prolonged-Course Antibiotic Therapy in a Multicenter, Propensity Score-Matched Cohort. Clin Infect Dis. 2018 Jan 6;66(2):172-177. doi: 10.1093/cid/cix767.</citation>
    <PMID>29190320</PMID>
  </reference>
  <reference>
    <citation>Yahav D, Franceschini E, Koppel F, Turjeman A, Babich T, Bitterman R, Neuberger A, Ghanem-Zoubi N, Santoro A, Eliakim-Raz N, Pertzov B, Steinmetz T, Stern A, Dickstein Y, Maroun E, Zayyad H, Bishara J, Alon D, Edel Y, Goldberg E, Venturelli C, Mussini C, Leibovici L, Paul M; Bacteremia Duration Study Group. Seven Versus 14 Days of Antibiotic Therapy for Uncomplicated Gram-negative Bacteremia: A Noninferiority Randomized Controlled Trial. Clin Infect Dis. 2019 Sep 13;69(7):1091-1098. doi: 10.1093/cid/ciy1054.</citation>
    <PMID>30535100</PMID>
  </reference>
  <reference>
    <citation>Huttner A, Albrich WC, Bochud PY, Gayet-Ageron A, Rossel A, Dach EV, Harbarth S, Kaiser L. PIRATE project: point-of-care, informatics-based randomised controlled trial for decreasing overuse of antibiotic therapy in Gram-negative bacteraemia. BMJ Open. 2017 Jul 13;7(7):e017996. doi: 10.1136/bmjopen-2017-017996.</citation>
    <PMID>28710229</PMID>
  </reference>
  <reference>
    <citation>Schroeder S, Hochreiter M, Koehler T, Schweiger AM, Bein B, Keck FS, von Spiegel T. Procalcitonin (PCT)-guided algorithm reduces length of antibiotic treatment in surgical intensive care patients with severe sepsis: results of a prospective randomized study. Langenbecks Arch Surg. 2009 Mar;394(2):221-6. doi: 10.1007/s00423-008-0432-1. Epub 2008 Nov 26.</citation>
    <PMID>19034493</PMID>
  </reference>
  <reference>
    <citation>Nobre V, Harbarth S, Graf JD, Rohner P, Pugin J. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. Am J Respir Crit Care Med. 2008 Mar 1;177(5):498-505. Epub 2007 Dec 20.</citation>
    <PMID>18096708</PMID>
  </reference>
  <reference>
    <citation>Corey GR, Stryjewski ME, Everts RJ. Short-course therapy for bloodstream infections in immunocompetent adults. Int J Antimicrob Agents. 2009;34 Suppl 4:S47-51. doi: 10.1016/S0924-8579(09)70567-9.</citation>
    <PMID>19931818</PMID>
  </reference>
  <reference>
    <citation>Havey TC, Fowler RA, Pinto R, Elligsen M, Daneman N. Duration of antibiotic therapy for critically ill patients with bloodstream infections: A retrospective cohort study. Can J Infect Dis Med Microbiol. 2013 Fall;24(3):129-37.</citation>
    <PMID>24421823</PMID>
  </reference>
  <reference>
    <citation>Corona A, Wilson AP, Grassi M, Singer M. Prospective audit of bacteraemia management in a university hospital ICU using a general strategy of short-course monotherapy. J Antimicrob Chemother. 2004 Oct;54(4):809-17. Epub 2004 Sep 16.</citation>
    <PMID>15375106</PMID>
  </reference>
  <reference>
    <citation>Cosgrove SE. The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. Clin Infect Dis. 2006 Jan 15;42 Suppl 2:S82-9.</citation>
    <PMID>16355321</PMID>
  </reference>
  <reference>
    <citation>Maragakis LL, Perencevich EN, Cosgrove SE. Clinical and economic burden of antimicrobial resistance. Expert Rev Anti Infect Ther. 2008 Oct;6(5):751-63. doi: 10.1586/14787210.6.5.751. Review.</citation>
    <PMID>18847410</PMID>
  </reference>
  <reference>
    <citation>Evans HL, Lefrak SN, Lyman J, Smith RL, Chong TW, McElearney ST, Schulman AR, Hughes MG, Raymond DP, Pruett TL, Sawyer RG. Cost of Gram-negative resistance. Crit Care Med. 2007 Jan;35(1):89-95.</citation>
    <PMID>17110877</PMID>
  </reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>February 24, 2020</study_first_submitted>
  <study_first_submitted_qc>February 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 2, 2020</study_first_posted>
  <last_update_submitted>May 27, 2020</last_update_submitted>
  <last_update_submitted_qc>May 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hvidovre University Hospital</investigator_affiliation>
    <investigator_full_name>Thomas Benfield</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>Gram-negative bacteremia</keyword>
  <keyword>Urinary tract infection</keyword>
  <keyword>Shortened antibiotic treatment</keyword>
  <keyword>Bacterial infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
    <mesh_term>Bacteremia</mesh_term>
    <mesh_term>Bacterial Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 6, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/68/NCT04291768/SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

